食管疾病2025，Vol.7Issue(2)：148-156,9.DOI:10.15926/j.cnki.issn2096-7381.2025.02.014
局部晚期可切除食管癌新辅助免疫治疗研究进展
Advances in Neoadjuvant Immunotherapy for Locally Advanced Resectable Esophageal Cancer
乔治 1张金峰 1杨英男 1王校媛 1凌晓东 1马建群1
作者信息
- 1. 哈尔滨医科大学附属肿瘤医院胸外科,黑龙江 哈尔滨,150081
- 折叠
摘要
Abstract
Surgical resection is currently the preferred method for treating locally advanced resectable esophageal cancer.However,the high recurrence rate associated with surgery alone poses a significant threat to the long-term survival of patients,making a multimodal treatment strategy centered around surgery the preferred choice for esophageal cancer treatment.within this comprehensive treatment framework,neoadjuvant immunotherapy has shown significant advantages in improving patient survival rates compared to traditional neoadjuvant therapies,without a significant increase in the risk of adverse reactions.These advantages suggest that neoadjuvant immunotherapy has great potential for application in the treatment of esophageal cancer.This article aims to provide a systematic review of the current application of neoadjuvant immunotherapy in the clinical treatment of esophageal cancer.关键词
食管癌/免疫抑制剂/新辅助免疫治疗/免疫检查点Key words
esophageal cancer/immune inhibitors/neoadjuvant immunotherapy/immune checkpoint分类
医药卫生引用本文复制引用
乔治,张金峰,杨英男,王校媛,凌晓东,马建群..局部晚期可切除食管癌新辅助免疫治疗研究进展[J].食管疾病,2025,7(2):148-156,9.
